[ad_1]
Last week, Pfizer announced that its vaccine candidate has been shown to be 90 percent effective after testing in the third phase.
Now come more promising vaccine studies, this time from the American company Moderna.
Their vaccine has been shown to be 94.5 percent effective, according to a new study involving 95 patients.
The company will now seek permission from the US FDA, which regulates drugs and vaccines, writes The Guardian.
Better terms than the Pfizer candidate
Moderna has previously said that the vaccine will not be distributed outside the United States until next year. Before the turn of the year, they say they are ready to supply the United States with 20 million doses. Starting next year, they hope to be able to produce between 500 million and 1 billion doses a year.
The vaccine has been developed using the same technology that BioNTech uses in researching its vaccine candidate.
However, according to The Guardian, Moderna has an advantage, as its vaccine can be stored at the same temperature as a refrigerator up to 30 degrees. The Pfizer candidate, on the other hand, requires a temperature between minus 70 and 80 degrees Celsius. However, modern vaccines are slightly more expensive.
Following the announcement of Moderna’s test results, the Stockholm Stock Exchange rose.
Pfizer’s vaccine is in its final stages
It consists of the mRNA of the genetic code.
